MC2309A1 - Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs - Google Patents

Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs

Info

Publication number
MC2309A1
MC2309A1 MC912309D MC2309D MC2309A1 MC 2309 A1 MC2309 A1 MC 2309A1 MC 912309 D MC912309 D MC 912309D MC 2309 D MC2309 D MC 2309D MC 2309 A1 MC2309 A1 MC 2309A1
Authority
MC
Monaco
Prior art keywords
carotene
vitamins
beta
treatment
vascular accidents
Prior art date
Application number
MC912309D
Other languages
English (en)
French (fr)
Inventor
Hennekens Charles
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of MC2309A1 publication Critical patent/MC2309A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MC912309D 1990-10-01 1991-09-27 Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs MC2309A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59202490A 1990-10-01 1990-10-01

Publications (1)

Publication Number Publication Date
MC2309A1 true MC2309A1 (fr) 1993-09-27

Family

ID=24368959

Family Applications (1)

Application Number Title Priority Date Filing Date
MC912309D MC2309A1 (fr) 1990-10-01 1991-09-27 Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs

Country Status (12)

Country Link
US (1) US5871766A (xx)
EP (1) EP0551427A4 (xx)
JP (1) JPH06501695A (xx)
KR (1) KR19980703596A (xx)
AU (1) AU660630B2 (xx)
BG (1) BG97678A (xx)
BR (1) BR9106938A (xx)
CA (1) CA2093008A1 (xx)
HU (1) HUT64837A (xx)
MC (1) MC2309A1 (xx)
RU (1) RU2126679C1 (xx)
WO (1) WO1992005780A1 (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61197774A (ja) * 1985-02-27 1986-09-02 Sanden Corp 冷媒圧縮機用バルブプレ−ト
CA2061477A1 (en) * 1991-03-25 1992-09-26 Lawrence J. Daher Analgesic composition containing beta-carotene
DK0689426T3 (da) * 1993-03-22 2000-10-30 Cognis Australia Pty Ltd Terapeutisk middel til behandling af melanomer
AU700689B2 (en) * 1993-03-22 1999-01-14 Betatene Pty Ltd Therapeutic agent for the treatment of melanomas
JPH08510995A (ja) * 1993-03-22 1996-11-19 ベータティーン・リミテッド 水分散性治療用化合物
US20040180865A1 (en) * 1993-06-04 2004-09-16 Jeffry W. Kreamer Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
US6262109B1 (en) 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
JP2001522229A (ja) * 1997-04-02 2001-11-13 ザ・ジヤクソン・ラボラトリー 抗酸化剤タンパク質２、遺伝子及びそれらの使用方法
WO1998045241A2 (en) 1997-04-04 1998-10-15 Henkel Corporation Lutein esters having high bioavailability
IL121112A (en) 1997-06-19 2005-11-20 Lycored Natural Prod Ind Ltd Synergistic pharmaceutical or dietary compositionscomprising lycopene and vitamin e for preventing ldl oxidation
WO1998057622A1 (en) * 1997-06-19 1998-12-23 Lycored Natural Products Industries Ltd. Synergistic compositions for lycopene and vitamin e for the prevention of ldl oxidation
US6914073B2 (en) 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
EP1036510B1 (en) * 1999-03-18 2004-01-07 Bristol-Myers Squibb Company Vitamin formulation for cardiovascular health
US6805880B1 (en) * 1999-08-20 2004-10-19 Ferrosan A/S Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
US6582721B1 (en) 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
US20030104090A1 (en) * 2000-05-05 2003-06-05 Levy Pedro E. Supplements containing annatto extracts and carotenoids and methods for using the same
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
EP1273297A1 (en) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction)
GB2380481B (en) * 2001-08-22 2003-12-03 Cambridge Theranostics Ltd Means for treatment of atherosclerosis
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7145025B2 (en) * 2002-07-29 2006-12-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1750723A1 (en) 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US7351424B2 (en) * 2004-07-22 2008-04-01 Bio Lut S.A. De C.V. Enhanced purity trans-lutein-ester compositions and methods of making same
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
US20060167319A1 (en) * 2004-10-01 2006-07-27 Lockwood Samuel F Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids
US20070065487A1 (en) * 2005-09-21 2007-03-22 Bio Lut S.A. De C.V. Trans-lutein xantophyll ester of high purity and high bioavailability in micellar solution and a process for the preparation thereof
US20070135521A1 (en) * 2005-12-14 2007-06-14 Yamaha Hatsudoki Kabushiki Kaisha Agent for Preventing Metabolic Syndrome
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
AU2014285095A1 (en) * 2013-07-03 2016-02-25 Barrie Tan CoQ10 (ubiquinone, ubiquinol), vitamin A (retinoic acid, retinol), vitamin E (tocotrienol, tocopherol) and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853993A (en) * 1973-05-01 1974-12-10 Univ Virginia Process for increasing oxygen diffusivity and method for treating atherosclerosis
JPS6053031B2 (ja) * 1978-03-31 1985-11-22 武田薬品工業株式会社 スピロ化合物およびその製造方法
US4491574A (en) * 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
ATE122885T1 (de) * 1984-01-28 1995-06-15 Roshdy Ismail Mittel zur behandlung von herzerkrankungen.
US5346488A (en) * 1985-04-08 1994-09-13 The General Hospital Corporation Laser-induced ablation of atherosclerotic plaque
EP0204987B1 (de) * 1985-05-15 1991-11-21 Roshdy Dr. Ismail Vitamin E-haltiges Mittel zur Verbesserung der Eigenschaften des Blutes
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
JP2619491B2 (ja) * 1988-08-11 1997-06-11 サントリー株式会社 アスタキサンチン含有組成物
CA2011651A1 (en) * 1989-03-08 1990-09-08 Gerald Shklar Composition and method for inducing tumor regression
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
EP0746202A4 (en) * 1992-01-06 1997-06-25 Health Maintenance Programs COMPOSITION CONTAINING A PHARMACEUTICALLY ACTIVE ANTI-OXIDANT AND METHOD FOR USE IN THE PREVENTION AND TREATMENT OF RESTENOSIS AFTER ANGIOPLASTY
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
IL104736A0 (en) * 1992-03-27 1993-06-10 Zeagen Inc Method for producing beta-carotene using a fungal mated culture
US5328845A (en) * 1992-03-27 1994-07-12 Universal Foods Corporation Fungal negative microorganism capable of producing high levels of beta-carotene
EP0643692B1 (en) * 1992-06-04 1999-11-24 Betatene Pty. Ltd. High cis beta-carotene composition
US5310554A (en) * 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
JPH08510995A (ja) * 1993-03-22 1996-11-19 ベータティーン・リミテッド 水分散性治療用化合物
US5607839A (en) * 1993-07-22 1997-03-04 Nippon Oil Company, Ltd. Bacteria belonging to new genus process for production of carotenoids using same
US5589468A (en) * 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients

Also Published As

Publication number Publication date
AU660630B2 (en) 1995-07-06
KR19980703596A (ko) 1998-12-05
WO1992005780A1 (en) 1992-04-16
US5871766A (en) 1999-02-16
EP0551427A4 (en) 1993-09-22
EP0551427A1 (en) 1993-07-21
BR9106938A (pt) 1993-09-28
BG97678A (en) 1994-03-31
CA2093008A1 (en) 1992-04-02
RU2126679C1 (ru) 1999-02-27
JPH06501695A (ja) 1994-02-24
HU9300950D0 (en) 1993-06-28
HUT64837A (en) 1994-03-28
AU8862191A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
MC2309A1 (fr) Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs
IT1211692B (it) Dispositivo per l'incontinenza orinaria femminile
IT1227260B (it) Dieteri utilizzabili nella preparazione di catalizzatori ziegler-natta
BE889327A (fr) Preparations pharmaceutiques a base de peroxydes et d'erythromycines pour le traitement topique de l'acne
IL90128A0 (en) Emulsion of pesticidal oil in water and process for its use
FR2607699B1 (fr) Preparation cosmetique antisolaire pour le visage et le corps
EP0273763A3 (en) Fluorine-containing polymers and oxygen-permeating articles composed of said polymers
GB8919896D0 (en) Concentrates of modifying agents in polymers
GB2223225B (en) Neutrophil-activating factor: its production and use in treatment
ZA876435B (en) The use of scr's in extended retarding
EP0427781A4 (en) Ozonides of terpenes and their medical uses
PH23866A (en) Body lubricating and cleansing fluid
TR26234A (tr) KüKüRTLE HIDROKARBON AKINTILARIN KOSTIK ICERMEYE- CEK BICIMDE KüKüRT MUHTEVASININ AZALTILMASI
FR2548538B1 (fr) Production d'interferon humain et procede pour le dosage de l'aptitude du sang a produire de l'interferon
EG19540A (en) Medicament pour le traitement de la dermatite
GB8912373D0 (en) Medicament for various skin and ulcer disorders
EP0412641A3 (en) Use of vitamin d in retinopathy
FR2640287B1 (fr) Dispositif pour tresser les cheveux et les fils
FI881648A (fi) Shampookoostumuksia
FR2645564B3 (fr) Escalier de securite pour evacuer les immeubles en cas de danger
KR900004588U (ko) 회전식 당구대
PL272720A1 (en) Bath liquid with gentle skin action
FR2632163B3 (fr) Sous-vetements pour femmes
KR890000009U (ko) 이앙기의 식입 포오크와 식모침
KR870018104U (ko) 무동력 자동침전 및 역 세척장치